| Recombinant anti-HER2 humanized monoclonal antibody (Shenzhen Main Luck Pharmaceuticals) |
|
Phase 1 Clinical |
Shenzhen Main Luck Pharmaceuticals Inc |
Breast Neoplasms |
Details
|
| Pertuzumab biosimilar (CTTQ) |
TQB-2440 |
Phase 3 Clinical |
Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd |
Breast Neoplasms |
Details
|
| Recombinant humanized anti-HER2 antibody (Hisun Pharma) |
|
Phase 3 Clinical |
Zhejiang Hisun Pharmaceutical Co Ltd |
Breast Neoplasms |
Details
|
| JRF-103 |
JRF103; JRF-103 |
Phase 2 Clinical |
Shenzhen Jinrui Foundation Biotechnology Co Ltd |
Solid tumours |
Details
|
| Trastuzumab biosimilar(Aprogen/Nichi-Iko) |
AP-06 |
Phase 3 Clinical |
Nichi-Iko Pharmaceutical Co Ltd, Aprogen |
Breast Neoplasms |
Details
|
| Anti-HER2 CAR T-cell therapy (Baylor College of Medicine/The Hospital for Sick Children/Texas Children's Hospital/The Methodist Hospital System ) |
|
Phase 1 Clinical |
Baylor College Of Medicine, The Hospital For Sick Children, Texas Children'S Hospital, The Methodist Hosp Research Institute |
Sarcoma |
Details
|
| SSGJ-706 |
SSGJ-706 |
Phase 1 Clinical |
Shanghai Cp Guojian Pharmaceutical Co Ltd |
Solid tumours; Lymphoma |
Details
|
| PM-3002 |
PM-3002 |
Phase 1 Clinical |
Biotheus Inc |
|
Details
|
| 99mTc- ADAPT6 |
99mTc- ADAPT6; ADAPT6; SNA-018 |
Phase 1 Clinical |
Uppsala University, Kth Royal Institute Of Technology |
Breast Neoplasms |
Details
|
| BAY-2701439 |
BAY-2701439 |
Phase 1 Clinical |
Bayer AG |
Neoplasms |
Details
|
| TAA-013 |
TAA-013 |
Phase 3 Clinical |
Tot Biopharm Co Ltd |
Breast Neoplasms |
Details
|
| HL-02 |
HL-02 |
Phase 3 Clinical |
Hualan Genetic Engineering Co Ltd |
Breast Neoplasms |
Details
|
| TGFBeta-resistant-HER2-EBV-CTLs |
TGFBeta-resistant-HER2-EBV-CTLs |
Phase 1 Clinical |
Baylor College Of Medicine |
Neoplasms |
Details
|
| Trastuzumab biosimilar (United BioPharma) |
UB-921 |
Phase 1 Clinical |
United Biopharma Inc |
Breast Neoplasms |
Details
|
| IBPM002BZ (Inbiopro Solutions) |
IBPM-002BZ |
Clinical |
Inbiopro Solutions |
Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Colorectal Neoplasms |
Details
|
| Trastuzumab biosimilar (Hualan Biological Engineering) |
|
Phase 1 Clinical |
Hualan Genetic Engineering Co Ltd |
Stomach Neoplasms; Breast Neoplasms |
Details
|
| IBPM003TZ (Inbiopro Solutions) |
IBPM-003TZ |
Clinical |
Inbiopro Solutions |
Breast Neoplasms |
Details
|
| PB-357 |
PB-357 |
Phase 1 Clinical |
Pfizer Inc |
Neoplasms |
Details
|
| Anti-HER2 CAR T-cell therapy (Seattle Children's Hospital) |
|
Phase 1 Clinical |
Seattle Children'S Research Institute |
Central Nervous System Neoplasms |
Details
|
| KSP-QRH-E3-IRDye800 |
|
Phase 1 Clinical |
University Of Michigan |
Cholangiocarcinoma |
Details
|
| Recombinant anti-HER2 human monoclonal antibody-DM1 (Hisun Pharm/Mabworks Biotech) |
HS-630; HS630 |
Phase 1 Clinical |
Zhejiang Hisun Pharmaceutical Co Ltd, Beijing Mabworks Biotech Co Ltd |
Breast Neoplasms |
Details
|
| SHR-A1201 |
SHR-A1201 |
Phase 1 Clinical |
Jiangsu Hengrui Medicine Co Ltd |
Breast Neoplasms |
Details
|
| Anti-CD3 and anti-HER2 BiTE-expressing T cell (MedImmune) |
|
Phase 2 Clinical |
University Of Michigan, Huazhong University Of Science And Technology, University Of Virginia Cancer Center, Medimmune |
Breast Neoplasms |
Details
|
| AU-101 |
AU-101 |
Phase 2 Clinical |
Aurora Biopharma |
Glioblastoma; Osteosarcoma; Breast Neoplasms |
Details
|
| 68Ga-anti-HER2 nanobodies (Universite Libre de Bruxelles) |
|
Phase 1 Clinical |
Universite Libre De Bruxelles |
Breast Neoplasms |
Details
|
| MX-402 |
MX-402 |
Phase 1 Clinical |
Medvax Technologies |
Stomach Neoplasms |
Details
|
| Recombinant anti-HER2 subdomain II humanized monoclonal antibody(Livzon) |
LZM-005 |
Phase 1 Clinical |
Livzon Pharmaceutical Group Inc |
Breast Neoplasms |
Details
|
| Trastuzumab biosimilar (BioXpress) |
BXT-2318; BX-2318 |
Clinical |
Bioxpress Therapeutics Sa |
Stomach Neoplasms; Metastatic breast cancer |
Details
|
| 99m-Tc labeled anti-HER2 single domain antibody (NanoMab) |
99mTc-NM-02 |
Phase 1 Clinical |
Nanomab Technology Ltd |
Breast Neoplasms |
Details
|
| Pertuzumab biosimilar (Xuanzhu/SL) |
KM-118; KM118; XZP-KM118 |
Phase 1 Clinical |
Beijing Sl Pharmaceutical Co Ltd |
Breast Neoplasms |
Details
|
| SSGJ-612 |
SSGJ-612 |
Phase 1 Clinical |
Shanghai Cp Guojian Pharmaceutical Co Ltd |
Solid tumours |
Details
|
| Pertuzumab biosimilar (CinnaGen) |
|
Phase 3 Clinical |
Cinnagen |
Breast Neoplasms |
Details
|
| Sirotinib Maleate |
XZP-5491 |
Phase 1 Clinical |
Shandong Xuanzhu Pharmaceutical Technology Co Ltd |
Stomach Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung |
Details
|
| GB-251 |
GB-251; NBT-828; GB221-NBT828 ADC-1 |
Phase 1 Clinical |
Genor Biopharma Co Ltd, Newbio Therapeutics Inc |
Breast Neoplasms; Metastatic breast cancer |
Details
|
| Puvitinib |
|
Phase 1 Clinical |
Suzhou Teligene Ltd |
Solid tumours |
Details
|
| KY-1701 |
KY-1701 |
Phase 1 Clinical |
Jiangsu Kanion Pharmaceutical Co Ltd |
Breast Neoplasms |
Details
|
| GB-235 |
GB-235 |
Phase 1 Clinical |
Genor Biopharma Co Ltd |
Breast Neoplasms |
Details
|
| Pertuzumab biosimilar (Jushi Biopharmaceutical ) |
|
Phase 1 Clinical |
Jushi Biopharmaceutical Co Ltd |
Breast Neoplasms; Metastatic breast cancer |
Details
|
| Epertinib |
S-222611 |
Phase 2 Clinical |
Shionogi & Co Ltd |
Neoplasms |
Details
|
| AU-105 |
AU-105 |
Phase 2 Clinical |
Aurora Biopharma |
Glioblastoma |
Details
|
| 99mTc-DARPinG3 |
99mTc-DARPinG3; 99mTc-DARPinG-3 |
Clinical |
Tomsk National Research Medical Center Of The Russian Academy Of Sciences |
Breast Neoplasms |
Details
|
| I-025-A |
I-025-A |
Phase 1 Clinical |
Shanghai Pharmaceuticals Holding Co Ltd |
Breast Neoplasms |
Details
|
| Trastuzumab biosimilar (Zhejiang Hisun Pharmaceutical) |
HS-022 |
Phase 1 Clinical |
Zhejiang Hisun Pharmaceutical Co Ltd |
Breast Neoplasms |
Details
|
| HER2/neu cancer vaccine (University of Washington/Corixa/GSK) |
|
|
University Of Washington |
|
Details
|
| CP-724714 |
CP-724714 |
|
Pfizer Pharmaceuticals Ltd (China) |
|
Details
|
| Mubritinib |
TAK-165 |
|
Takeda Pharmaceutical Co Ltd |
|
Details
|
| MBS-301 |
MBS-301 |
Phase 1 Clinical |
Beijing Mabworks Biotech Co Ltd |
Stomach Neoplasms; Breast Neoplasms |
Details
|
| Dual-targeting HER2 and PD-L1 CAR-T Cell Therapy (Sichuan University) |
|
|
Sichuan University |
|
Details
|
| MP-412 |
AV-412; MP-412 |
|
Mitsubishi Tanabe Pharma |
|
Details
|
| BVAC-B vaccine (Cellid) |
BVAC-B |
|
Cellid Company |
|
Details
|
| TAK-285 |
TAK-285 |
|
Takeda |
|
Details
|
| BCD-147 |
BCD-147 |
|
Biocad |
|
Details
|
| M-802(Wuhan Yzy Biopharma/CSPC Pharmaceutical) |
M-802 |
Phase 1 Clinical |
Wuhan Yzy Biopharma Co Ltd, CSPC Pharmaceutical Group Ltd |
Solid tumours; Ovarian Neoplasms; Stomach Neoplasms; Breast Neoplasms |
Details
|
| Recombinant anti-HER2 humanized monoclonal antibody complex |
B-002 |
Phase 1 Clinical |
Shanghai Pharmaceuticals Holding Co Ltd |
Breast Neoplasms |
Details
|
| MP-0274 |
DARPin-41; SPA-28; CME-114; CME-115; CME-118; CME-119; MP-0274 |
|
Molecular Partners Ag |
|
Details
|
| Anti-HER2 monoclonal antibody-MCC-DM1 conjugate (Shanghai Pharma) |
B-003 (Shanghai Pharma) |
Phase 1 Clinical |
Shanghai Crosslink Pharmaceutical R & D Co Ltd, Shanghai Pharmaceuticals Holding Co Ltd |
Breast Neoplasms |
Details
|
| MEDI-4276 |
MEDI-4276 |
|
Medimmune Llc |
|
Details
|
| RG-6148 |
RG-6148; DHES-0815A |
|
F. Hoffmann-La Roche Ltd |
|
Details
|
| Hemay-022 |
Hemay-022 |
Phase 3 Clinical |
Tianjin Hemay Pharmaceutical Co Ltd, Xiajiang Hemei Pharmaceutical Co Ltd |
Breast Neoplasms; Foodborne Diseases |
Details
|
| DZD-1516 |
DZD-1516 |
Phase 1 Clinical |
Dizal (Jiangsu) Pharmaceutical Co Ltd |
Breast Neoplasms |
Details
|
| Recombinant anti-HER2 domain II humanized monoclonal antibody (Qilu Pharmaceutical) |
|
Phase 1 Clinical |
Qilu Pharmaceutical Co Ltd |
Breast Neoplasms |
Details
|
| Recombinant human ErbB3 fragment vaccine (Zensun) |
rhErbB3-f |
Phase 1 Clinical |
Zensun (Shanghai) Sci&Tech Co Ltd |
Neoplasms |
Details
|
| Recombinant Humanized Anti-Human Epidermal Growth Factor Receptor Monoclonal Antibody and the Dolastatins Derivative DUO5 Conjugated |
ZV0203; ZV203 |
Phase 1 Clinical |
Zhejiang Hisun Pharmaceutical Co Ltd, Zhejiang Zova Biotherapeutics Inc, Concortis Biosystems Corp |
Solid tumours |
Details
|
| Selatinib Ditosilate |
QLNC-120 |
Phase 2 Clinical |
Qilu Antibiotics (Linyi) Pharmaceutical Co Ltd, Qilu Pharmaceutical Co Ltd |
Breast Neoplasms |
Details
|
| Allitinib Tosylate |
AST-6; ALS-1306; AST-1306 |
Phase 2 Clinical |
Shanghai Allist Pharmaceutical Technology Co Ltd |
Breast Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| AMX-3009 Maleate |
AMX-3009; AMX3009马来酸 |
Phase 1 Clinical |
Anrun Medicine Technology (Suzhou) Co Ltd |
Solid tumours; Stomach Neoplasms; Pancreatic Neoplasms; Breast Neoplasms |
Details
|
| BAT-1006 |
BAT-1006 |
Phase 1 Clinical |
Bio-Thera Solutions Ltd |
Solid tumours |
Details
|
| Pertuzumab biosimilar(EirGenix) |
EG-1206A; EG-1206-A |
Phase 1 Clinical |
Eirgenix Inc |
Breast Neoplasms |
Details
|
| BC-004 |
BC-004 |
Phase 1 Clinical |
Shandong Buchang Pharmaceuticals Co Ltd |
Solid tumours; Breast Neoplasms |
Details
|
| Recombinant anti-HER2 humanized monoclonal antibody (Shanghai Institute of Biological Products) |
SIBP-01 |
Phase 3 Clinical |
Shanghai Institute Of Biological Products Co Ltd |
Stomach Neoplasms; Breast Neoplasms |
Details
|
| IMM-2902 |
IMM-2902 |
Phase 1 Clinical |
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd |
Solid tumours; Stomach Neoplasms; Breast Neoplasms |
Details
|
| Recombinant anti-HER2 subdomain II and subdomain IV humanized monoclonal antibody(Xuanzhu) |
XZP-KM257; KM257/252; KM-257 |
Phase 1 Clinical |
Beijing Kangming Bio New Drug Development Co Ltd |
Solid tumours |
Details
|
| Recombinant anti-HER2 humanized HuA21 monoclonal antibody(Hankemab) |
|
Phase 1 Clinical |
|
Solid tumours |
Details
|
| NIP-142 |
NIP-142 |
Phase 1 Clinical |
|
Carcinoma, Non-Small-Cell Lung |
Details
|
| trastuzumab biosimilar (Hetero) |
Ado-Trastuzumab biosimilar (Hetero) |
Phase 3 Clinical |
Hetero Drugs Ltd |
Neoplasms |
Details
|
| Trastuzumab biosimilar (BioIntegrator) |
BI-Mab-03 |
Phase 1 Clinical |
Biointegrator Llc |
Breast Neoplasms |
Details
|
| TT-16 |
TT-16 |
Phase 1 Clinical |
Tessa Therapeutics Ltd |
Solid tumours |
Details
|
| Trastuzumab biosimilar (NeuClone/Serum Institute of India) |
|
Phase 1 Clinical |
Serum Institute Of India Ltd, Neuclone |
Stomach Neoplasms; Breast Neoplasms |
Details
|
| MB-103 |
MB-103 |
Phase 1 Clinical |
Mustang Bio Inc, City Of Hope National Medical Center |
Glioblastoma; Brain metastases |
Details
|
| HER2(EQ)BBzeta/CD19 T cells (City of Hope) |
|
Phase 1 Clinical |
Mustang Bio Inc, City Of Hope National Medical Center |
Glioma |
Details
|
| SPH-5030 |
SPH-5030 |
Phase 1 Clinical |
Shanghai Pharmaceuticals Holding Co Ltd |
Solid tumours |
Details
|
| ORIC-114 |
ORIC-114 |
Phase 1 Clinical |
Voronoi |
Solid tumours; Carcinoma, Non-Small-Cell Lung |
Details
|
| HER2 cancer vaccine (BioLife Science) |
PEV-6; PEV-6A; IMU-131 |
Phase 2 Clinical |
Pevion Biotech Ltd |
Esophageal Neoplasms; Stomach Neoplasms; Gastrointestinal Neoplasms; Adenocarcinoma |
Details
|
| MT-5111 |
MT-5111 |
Phase 1 Clinical |
Molecular Templates Inc |
Solid tumours |
Details
|
| BDC-1001 |
BDC-1001 |
Phase 2 Clinical |
Bolt Biotherapeutics Inc |
Solid tumours |
Details
|
| Iodine-131-SGMIB anti-HER2 monoclonal antibody |
[131I]-SGMIB Anti-HER2-VHH1; 131I-SGMIB-anti-HER2-VHH1; Iodine-131-SGMIB-anti-HER2-VHH1; CAM-H2 |
Phase 2 Clinical |
Camel-Ids Nv |
Stomach Neoplasms; Esophageal Neoplasms; Breast Neoplasms |
Details
|
| TAC01-HER2 |
TAC01-HER2 |
Phase 2 Clinical |
Triumvira Immunologics Inc |
Solid tumours |
Details
|
| NeuCeptin |
NeuCeptin |
Phase 1 Clinical |
Neuclone, Serum Institute Of India Ltd |
Stomach Neoplasms; Breast Neoplasms |
Details
|
| Anti-CD3-anti-HER2-activated T cells |
|
Phase 2 Clinical |
Transtarget |
Breast Neoplasms; Prostatic Neoplasms |
Details
|
| Pertuzumab biosimilar (Qilu Pharmaceutical) |
QL-1209 |
Phase 3 Clinical |
Qilu Pharmaceutical Co Ltd |
Breast Neoplasms |
Details
|
| AE-37/GP-2 vaccine |
AE-37 (Generex Biotechnology Corporation) |
Phase 2 Clinical |
Generex Biotechnology Corp |
Triple Negative Breast Neoplasms; Breast Neoplasms |
Details
|
| HER.CAR-CMV-specific-CTLs |
HER.CAR-CMV-specific-CTLs |
Phase 1 Clinical |
Baylor College Of Medicine |
Glioblastoma |
Details
|
| 4-1BBz CD19-Her2tG (Seattle Children's Hospital) |
|
Phase 1 Clinical |
Seattle Children'S Hospital |
Leukemia; Neoplasms; Lymphoma |
Details
|
| Autologous-HER2-specific-T-cells |
Autologous-HER2-specific-T-cells |
Phase 1 Clinical |
Baylor College Of Medicine |
Sarcoma; Brain Neoplasms |
Details
|
| Multiple 4SCAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) |
|
Phase 2 Clinical |
Shenzhen Geno-Immune Medical Institute |
Breast Neoplasms |
Details
|
| Autologous AdHER2 dendritic cell vaccine (National Cancer Institute) |
|
Phase 1 Clinical |
National Cancer Institute |
Neoplasms; Breast Neoplasms; Adenocarcinoma; Neoplasm Metastasis |
Details
|
| ALT-P7 |
HM2-MMAE; ALT-P7 |
Phase 1 Clinical |
Alteogen Inc |
Stomach Neoplasms; Breast Neoplasms |
Details
|
| Pertuzumab biosimilar（Hisun Pharm） |
HS-627; HS627 |
Phase 3 Clinical |
Zhejiang Hisun Pharmaceutical Co Ltd, Beijing Mabworks Biotech Co Ltd |
Breast Neoplasms |
Details
|
| TPIV-100 (TapImmune) |
TPIV-100 |
Phase 2 Clinical |
Mayo Clinic |
Carcinoma, Intraductal, Noninfiltrating; Breast Neoplasms; Breast Neoplasms, Male |
Details
|
| HER-2/Neu pulsed DC1 vaccine (University of Pennsylvania) |
|
Phase 1 Clinical |
University Of Pennsylvania, National Cancer Institute |
Breast Neoplasms |
Details
|
| CIDeCAR |
|
Phase 1 Clinical |
Bellicum Pharmaceuticals Inc, National Cancer Institute |
Osteosarcoma; Sarcoma; Neuroblastoma; Melanoma |
Details
|
| 89Zr-ss-Pertuzumab |
|
Phase 1 Clinical |
Genentech Inc |
Breast Neoplasms; Metastatic breast cancer |
Details
|
| HER-2 Specific CAR T Cell |
|
Phase 1 Clinical |
Pediatric Brain Tumor Consortium (Pbtc), St. Jude Children'S Research Hospital |
Ependymoma |
Details
|
| HER2.taNK |
NK-92/5.28.z |
Phase 1 Clinical |
Nantkwest Inc |
Glioblastoma |
Details
|
| Cinrebafusp alfa |
PRS-343 |
Phase 2 Clinical |
Pieris Pharmaceuticals |
Solid tumours; Stomach Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms |
Details
|
| 99mTc-HPArk2 |
99mTc-HPArk2; 99-mTc-HPArk-2 |
Phase 1 Clinical |
Peking Union Medical College Hospital |
Breast Neoplasms |
Details
|
| Recombinant anti-HER2 antibody-Tub114 |
DAC-001; DX126-262 |
Phase 2 Clinical |
Hangzhou Dac Biotech Company Ltd |
Stomach Neoplasms; Carcinoma, Transitional Cell; Breast Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung |
Details
|
| Pertuzumab biosimilar(Zydus Cadila) |
ZRC-3277 |
Phase 3 Clinical |
Zydus Cadila |
Breast Neoplasms |
Details
|
| PLB-1004 |
PLB-1004 |
Phase 1 Clinical |
Beijing Anshi Biotechnology Co Ltd |
Carcinoma, Non-Small-Cell Lung |
Details
|
| AB-201 (Artiva Biotherapeutics) |
|
Phase 1 Clinical |
Artiva Biotherapeutics Inc |
Solid tumours |
Details
|
| ETBX-021 |
ETBX-021 |
Phase 2 Clinical |
Nantbioscience Inc, Etubics Corp |
Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| CT-0508 |
|
Phase 1 Clinical |
Carisma Therapeutics Inc |
Digestive System Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Adenocarcinoma; Carcinoma, Squamous Cell; Carcinoma, Small Cell; Endometrial Neoplasms; Colorectal Neoplasms; Bile Duct Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Urinary Bladder Neoplasms; Biliary Tract Neoplasms; Carcinoma, Ductal; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Inflammatory Breast Neoplasms; Carcinoma, Ovarian Epithelial; Neoplasms; Stomach Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours |
Details
|
| SSGJ-705 |
SSGJ-705 |
Phase 1 Clinical |
Shanghai Cp Guojian Pharmaceutical Co Ltd |
Solid tumours; Neoplasms |
Details
|
| MRG-002 |
MRG-002 |
Phase 2 Clinical |
Shanghai Miracogen Inc |
Biliary Tract Neoplasms; Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Breast Neoplasms; Bile Duct Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma |
Details
|
| A-166 |
A-166 |
Phase 2 Clinical |
Sichuan Kelun Pharmaceutical Co Ltd |
Mouth Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Prostatic Neoplasms; Carcinoma, Mucoepidermoid; Peritoneal Neoplasms; Bile Duct Neoplasms; Colorectal Neoplasms; Urologic Neoplasms; Urinary Bladder Neoplasms; Lip Neoplasms; Laryngeal Neoplasms; Tonsillar Neoplasms; Lung Neoplasms; Tongue Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours; Stomach Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Cystadenocarcinoma, Mucinous; Liver Neoplasms; Pancreatic Neoplasms; Salivary Gland Neoplasms; Skin Neoplasms; Colonic Neoplasms; Rare Diseases; Carcinoma, Transitional Cell; Neoplasms |
Details
|
| [89Zr]-Df-Trastuzumab |
|
Phase 1 Clinical |
University Of Alabama At Birmingham |
Solid tumours; Neoplasms; Breast Neoplasms |
Details
|
| Runimotamab |
BTRC-4017A; RG-6194 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Solid tumours; Neoplasms |
Details
|
| Sapitinib |
AZD-8931 |
Phase 2 Clinical |
Astrazeneca Pharmaceutical Co Ltd |
Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis |
Details
|
| Pertuzumab biosimilar(SL Pharma/Combio) |
|
Phase 1 Clinical |
Beijing Kangming Bio New Drug Development Co Ltd, Beijing Sl Pharmaceutical Co Ltd |
Inflammatory Breast Neoplasms; Breast Neoplasms; Metastatic breast cancer |
Details
|
| FDA022 Antibody Drug Conjugate |
|
Phase 1 Clinical |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd |
Solid tumours; Neoplasms |
Details
|
| HLX-22 |
AC-101; HLX-22 |
Phase 2 Clinical |
Shanghai Henlius Biotech Co Ltd |
Solid tumours; Stomach Neoplasms; Breast Neoplasms |
Details
|
| GQ-1005 |
GQ-1005; GQ1005 |
Phase 1 Clinical |
GeneQuantum Healthcare (Suzhou) Co Ltd |
Solid tumours; Neoplasms |
Details
|
| anti-HER2 ADC (Pfizer) |
PF-06804103 |
Phase 2 Clinical |
Pfizer Inc |
Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms |
Details
|
| YH-32367 |
ABL105; YH-32367 |
Phase 2 Clinical |
Abl Bio Inc |
Solid tumours; Stomach Neoplasms; Breast Neoplasms |
Details
|
| EX-101 |
EX-101; EX101 |
Phase 1 Clinical |
Guangzhou ASM Biomedical Technology Co Ltd |
Solid tumours |
Details
|
| XZP-5209 |
XZP-5209 |
Phase 1 Clinical |
|
Carcinoma, Non-Small-Cell Lung |
Details
|
| Tarloxotinib Bromide |
PR-610; TH-4000; SN-33999 |
Phase 2 Clinical |
Threshold |
Solid tumours; Carcinoma, Non-Small-Cell Lung |
Details
|
| DB-1303 |
DB-1303 |
Phase 2 Clinical |
Duality Biologics Co Ltd |
Solid tumours; Neoplasm Metastasis |
Details
|
| JSKN-003 |
JSKN-003 |
Phase 1 Clinical |
Alphamab Oncology |
Solid tumours; Neoplasms |
Details
|
| BB-1701 |
BB-1701 |
Phase 2 Clinical |
Baili Sikang Biomedicine (Hangzhou) Co Ltd |
Solid tumours; Carcinoma, Transitional Cell |
Details
|
| ORM-5029 |
ORM-5029 |
Phase 1 Clinical |
Orum Therapeutics Inc |
Solid tumours; Breast Neoplasms |
Details
|
| HER2/Neu GP2 vaccine(Greenwich LifeSciences Inc/NuGenerex Immuno Oncology) |
GLSI-100 |
Phase 3 Clinical |
Antigen Express Inc, Norwell Inc |
Breast Neoplasms |
Details
|
| SAR-443216 |
SAR-443216 |
Phase 1 Clinical |
Sanofi |
Stomach Neoplasms; Neoplasms; Breast Neoplasms; Lung Neoplasms |
Details
|
| Tesevatinib |
XL-647; KD-020; KD-019; EXEL-7647 |
Phase 2 Clinical |
Exelixis Inc |
Neoplasms; Glioblastoma; Breast Neoplasms; Brain Neoplasms; Polycystic Kidney, Autosomal Dominant; Brain metastases; Polycystic Kidney, Autosomal Recessive; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis |
Details
|
| ZN-A-1041 |
ZN-A-1041 |
Phase 1 Clinical |
Suzhou Zanrong Pharmaceutical Technology Co Ltd |
Solid tumours; Neoplasms; Breast Neoplasms |
Details
|
| DP-303c |
DP-303c; DP303c |
Phase 2 Clinical |
CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd |
Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Salivary Gland Neoplasms; Neoplasms; Breast Neoplasms; Metastatic breast cancer |
Details
|
| BAY-2927088 |
BAY-2927088; BAY2927088 |
Phase 1 Clinical |
Bayer Healthcare Company Ltd, Bayer AG |
Carcinoma, Non-Small-Cell Lung |
Details
|
| AIP-303 |
AIP-303 |
Phase 2 Clinical |
Advanced Imaging Projects |
Breast Neoplasms |
Details
|
| Larotinib Mesylate |
Z-650 |
Phase 3 Clinical |
Guangdong Dongyangguang Pharmaceutical Co Ltd |
Solid tumours; Esophageal Neoplasms; Pancreatic Neoplasms; Esophageal Squamous Cell Carcinoma |
Details
|
| Sunvozertinib |
DZD-9008 |
Phase 2 Clinical |
Dizal (Jiangsu) Pharmaceutical Co Ltd |
Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Carcinoma, Non-Small-Cell Lung |
Details
|
| KSP-910638-G |
KSP-910638G; KSP-910638-G |
Phase 1 Clinical |
University Of Michigan |
Gastrointestinal Neoplasms |
Details
|
| TAS-2940 |
TAS-2940 |
Phase 1 Clinical |
Taiho Oncology Inc |
Solid tumours; Glioblastoma; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| 99mTc-HE3-G3 |
99mTc-HE3-G3; 99-mTc-HE-3-G-3; 99m-Tc-HE-3-G-3; 99mTc-(HE)3-G3 |
Phase 1 Clinical |
Tomsk National Research Medical Center Of The Russian Academy Of Sciences |
Solid tumours; Breast Neoplasms |
Details
|
| 99mTc-MIRC213 |
99-mTc-MIRC-213 |
Phase 1 Clinical |
Peking Union Medical College Hospital |
Breast Neoplasms |
Details
|
| 99mTc-MIRC208 |
|
Clinical |
Beijing Cancer Hospital |
Neoplasms |
Details
|
| Gancotamab |
MM-302 |
Phase 2 Clinical |
Merrimack Pharmaceuticals Inc |
Ovarian Neoplasms; Breast Neoplasms |
Details
|
| FCN-411 |
FCN-411 |
Phase 2 Clinical |
Shanghai Fosun Pharmaceutical (Group) Co Ltd |
Lung Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| Pirotinib Hydrochloride |
KBP-5209 |
Phase 2 Clinical |
Shandong Xuanzhu Pharmaceutical Technology Co Ltd |
Solid tumours; Neoplasms; Breast Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| Trastuzumab biosimilar (Alteogen) |
ALT-L2; ALT-02; QL-1701; ALT-LS2 |
Phase 3 Clinical |
Alteogen Inc |
Stomach Neoplasms; Esophageal Neoplasms; Breast Neoplasms |
Details
|
| ARV-471 |
ARV-471; PF-07850327 |
Phase 2 Clinical |
Arvinas Inc |
Breast Neoplasms |
Details
|
| Varlitinib Ditosylate |
QBT-01; ARRY-543; SPS-4370; ASLAN-001; ARRY-334543 |
Phase 2 Clinical |
Array Biopharma |
Biliary Tract Neoplasms; Solid tumours; Stomach Neoplasms; Neoplasms; Pancreatic Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Bile Duct Neoplasms |
Details
|
| SHR-A1811 |
SHR-A1811 |
Phase 3 Clinical |
Jiangsu Hengrui Medicine Co Ltd, Suzhou Suncadia Biopharmaceuticals Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd |
Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Metastatic breast cancer; HR-positive breast cancer; Carcinoma, Non-Small-Cell Lung |
Details
|
| [18F]GE-226 |
ABY-002; ABY-025; ABY-0125; 68GaABY025; GE-226; [68Ga]-ABY-025; GE-226-[18F]; [111]In-ABY-025; ABY-025-[68Ga]; ABY-025-[111In]; Gallium-68-ABY-025; Indium-111-ABY-025; Fluorine-18-GE-226 |
Phase 3 Clinical |
Affibody Ab |
Breast Neoplasms |
Details
|
| ACE-1702 |
ACE-1702 |
Phase 1 Clinical |
Acepodia Taiwan Subsidiary |
Solid tumours; Stomach Neoplasms; Metastatic breast cancer; Neoplasm Metastasis |
Details
|
| GQ-1001 |
GQ-1001 |
Phase 2 Clinical |
GeneQuantum Healthcare (Suzhou) Co Ltd |
Solid tumours; Breast Neoplasms; Metastatic breast cancer |
Details
|
| IAH-0968 |
IAH-0968; IAH0968 |
Phase 2 Clinical |
Shenghe (China) Biopharmaceutical Co Ltd |
Solid tumours; Biliary Tract Neoplasms; Colorectal Neoplasms |
Details
|
| Pertuzumab biosimilar (Shanghai Henlius Biotech) |
HLX-11 |
Phase 3 Clinical |
Shanghai Henlius Biotech Co Ltd |
Breast Neoplasms; Metastatic breast cancer |
Details
|
| Zanidatamab zovodotin |
ZW-49 |
Phase 1 Clinical |
Zymeworks Inc |
Neoplasms |
Details
|
| XMT-2056 |
XMT-2056 |
Phase 1 Clinical |
Mersana Therapeutics Inc |
Stomach Neoplasms; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| Zenocutuzumab |
MCLA-128 |
Phase 2 Clinical |
Merus Nv |
Solid tumours; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| Anbenitamab |
KN-026 |
Phase 3 Clinical |
Suzhou Alphamab Co Ltd |
Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Breast Neoplasms; Lymphoma; Gastrointestinal Neoplasms |
Details
|
| Coprelotamab |
GB-221 |
Phase 3 Clinical |
Genor Biopharma Co Ltd |
Breast Neoplasms |
Details
|
| Trastuzumab monomethyl auristatin F |
FS-1502; LCB14-0110; LCB-14-0110 |
Phase 2 Clinical |
Legochembio |
Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| Trastuzumab biosimilar (Hanwha Biologics) |
HD-201 |
Phase 3 Clinical |
Hanwha Biologics |
Kidney Neoplasms; Breast Neoplasms |
Details
|
| Fidasimtamab |
IBI-315 |
Phase 1 Clinical |
Hanmi Pharmaceutical Co Ltd, Innovent Biologics(Suzhou) Co Ltd |
Solid tumours; Neoplasms |
Details
|
| ARX-788 |
ARX-788; NCB-001 |
Phase 3 Clinical |
Ambrx Inc |
Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Breast Neoplasms; Bile Duct Neoplasms |
Details
|
| Zanidatamab |
ZW-25 |
Phase 3 Clinical |
Zymeworks Inc |
Biliary Tract Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Breast Neoplasms; Bile Duct Neoplasms; Esophageal adenocarcinoma; Endometrial Neoplasms; Carcinosarcoma; Gastrointestinal Neoplasms |
Details
|
| DF-1001 |
DF-1001 |
Phase 2 Clinical |
Dragonfly Therapeutics Llc |
Solid tumours |
Details
|
A-Z
